KOSDAQBiotech & Pharma226330

SyntekaBio

₩940▲ 0.11%2026-11-18 close
Market Cap
₩22.8B
Turnover
₩45,653,212
Volume
50K
Shares out.
24.3M
PER
—
PBR
1.1×
EPS
-₩651
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue rising, but losses and audit issues remain

SyntekaBio's 2025 revenue rose to KRW 3.43 billion and cleared the sales threshold, but operating losses continue and a 2026 half-year review opinion refusal and re-audit remain open issues.

  1. 1

    Revenue growth: 2025 sales of KRW 3.43 billion (up 2,736.7% year on year); third-quarter 2026 sales of KRW 689 million (up 51.3% year on year).

  2. 2

    Losses persist: operating loss of KRW 10.8 billion in 2025, a loss in each of the four years from 2022 to 2025, though narrower than in 2024.

  3. 3

    Expansion: seven proprietary pipeline candidates disclosed, bio-better candidates across eight targets, and hit compounds for two targets from joint research with MSK.

  4. 4

    Contract cancellation: two agreements with Kymera Therapeutics, totaling about KRW 534 million, were terminated (disclosed November 16, 2026), and the amounts were not booked as revenue.

  5. 5

    Financials and audit: the debt ratio fell to 46.4% at end-2025 (75.3% in 2024), but the company received a review opinion refusal on its 2026 half-year statements and is pursuing a re-audit.

02

Business structure

SyntekaBio's business centers on AI drug discovery platforms. Its core offerings are the DeepMatcher candidate discovery service and LM-VS, a language-model-based virtual screening tool that the company launched in global markets as a SaaS product in the first half of 2025.

It also holds the Ab-ARS antibody optimization platform and the Neo-ARS neoantigen-based cancer vaccine discovery platform. In an October 2026 presentation, the company said KRW 3.1 billion of its 2025 sales of KRW 3.43 billion came from the AI drug discovery platform business.

Its other units include SI services that build digital platforms for biotech firms and IDC data-center services run from its ABS facility.

Customers are domestic and overseas pharmaceutical companies, biotech firms and research institutes, and it has run joint research with overseas partners such as Kymera Therapeutics and Memorial Sloan Kettering Cancer Center (MSK).

In September 2026 it put forward a charter amendment adding areas such as screening and diagnostics, precision medicine, veterinary drugs and vaccines, and pet health supplements for a shareholder meeting on September 15.

Its own pipeline now includes seven disclosed candidates, among them treatments for COPD, acute myeloid leukemia, Alzheimer's disease and colorectal cancer. On competition, the company says most domestic AI drug discovery platform firms remain in early commercialization with little or no revenue.

CEO Jeong Jong-sun has presented a dry-lab AI approach as a differentiated answer to China's wet-lab-centered development.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩500M-₩2.3B−508.2%
2025Q4₩1.8B-₩2.5B−141.5%
2026Q1₩400M-₩3.5B−830.1%
2026Q2₩400M-₩2.2B−494.9%
2026Q3₩700M-₩3.7B−532.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩200M-₩11.8B-₩4.5B−4833.0%−14.3%77.0%
2023₩100M-₩12.3B-₩11.4B−9947.9%−36.5%69.5%
2024₩100M-₩14.3B-₩7.2B−11804.0%−28.9%75.3%
2025₩3.4B-₩10.8B-₩17.4B−313.9%−54.7%46.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a disclosed annual basis, revenue was KRW 244 million in 2022, KRW 123 million in 2023 (down 49.4% year on year) and KRW 121 million in 2024 (down 2.0%), before jumping to KRW 3.43 billion in 2025 (up 2,736.7%). 2025 is the largest year and 2024 the smallest within 2022 to 2025.

The company attributed the 2025 revenue increase to the commercialization of its AI drug discovery platform. Operating loss was KRW 11.8 billion in 2022, KRW 12.3 billion in 2023 and KRW 14.3 billion in 2024, then narrowed to KRW 10.8 billion in 2025.

Operating margin moved from -4,833.0% in 2022 and -11,804.0% in 2024 to -313.9% in 2025. Net loss attributable to controlling shareholders widened to KRW 17.4 billion in 2025 from KRW 7.21 billion in 2024, and the disclosed net loss including non-controlling interests was also KRW 17.4 billion.

The company cited the base effect of a smaller derivative valuation gain from the prior year and a change in financing costs, including interest expense. Operating cash flow was negative in all four years, at -KRW 8.51 billion in 2022, -KRW 8.08 billion in 2023, -KRW 10.5 billion in 2024 and -KRW 10.6 billion in 2025.

On a quarterly basis, fourth-quarter 2025 sales of KRW 1.76 billion rose 286.2% from the prior quarter and accounted for more than half of full-year 2025 sales.

First-quarter 2026 sales of KRW 422 million fell 76.0% from the prior quarter, but sales then rose to KRW 449 million in the second quarter and KRW 689 million in the third, two straight quarters of growth. Operating loss widened from KRW 2.22 billion in the second quarter of 2026 to KRW 3.67 billion in the third.

Net loss attributable to controlling shareholders across the four quarters from the fourth quarter of 2025 through the third quarter of 2026 totaled KRW 14 billion. The debt ratio fell from 75.3% in 2024 to 46.4% in 2025, and total equity stood at KRW 31.8 billion at end-2025.

05

Industry analysis

The AI drug discovery industry depends on demand from global pharmaceutical companies seeking to cut the cost and time of candidate discovery.

However, CEO Jeong Jong-sun said at an October 2026 presentation that poor earnings at global AI drug discovery firms over the past decade have weakened market confidence in bio-AI overall. The company says many domestic AI drug discovery platform firms are still in early commercialization with little or no revenue.

On financing conditions, reports noted that SyntekaBio itself faced liquidity pressure from a rise in convertible bond put option exercises during 2025 amid a difficult funding environment across the sector.

On technology, the seven antibody bio-better lead candidates presented at MSK's event and LM-VS, which screens a chemical space of roughly 10 billion compounds, are positioned as complements to large-scale experimental screening.

Competitively, China is scaling wet-lab-centered drug development on large teams, capital and infrastructure, and the company presents AI-driven dry-lab methods as its response. The company also cites government AI support policies as a growth opportunity.

06

Outlook

The company set a goal of reaching breakeven (BEP) in 2026, stated in an October 10, 2026 presentation. To get there it plans to expand its asset program, which uses data-center-scale AI to discover candidates, validates them in large experiments, and pursues technology transfer (licensing).

In September 2026 it added bio-better candidates for four targets in metabolic disease, muscle loss and autoimmune disease using its Ab-ARS platform, bringing the total to eight targets with at least one candidate.

In November 2026 joint research with MSK produced hit compounds for two targets, with results to be published in a journal before a separate press release. It also targets at least 18 pre-IND development candidates by year-end.

Its own pipeline is aimed at clinical entry, with COPD and atopic dermatitis programs co-developed with QIMR Berghofer and Kanzen Biotechnology. The charter amendment is intended to widen revenue sources into screening, precision medicine and veterinary products.

On funding, reports say the payment date for a KRW 2 billion third-party share placement was moved to November 17, 2026, and a public offering of KRW 3 billion or more is under review.

In a March 2026 report, Eugene Investment & Securities analyst Park Jong-sun forecast 2026 sales of KRW 7.7 billion, up 125%, and a roughly 80% drop in operating loss. Quarterly sales from the first to third quarter of 2026 stayed in the hundreds of millions of won, far below that March forecast.

Terminating the Kymera projects removes their contribution, and the termination takes effect on November 30, 2026.

07

Valuation

PER
—
PBR
1.1×
ROE
-83.2%
EPS
-₩651
BPS
₩896
Dividend per share
₩0

Because net losses across the four quarters from the fourth quarter of 2025 through the third quarter of 2026 leave no earnings base, the price-to-earnings ratio cannot be calculated and earnings-based comparison does not apply. The price-to-book ratio sits around 1x, close to net asset value.

Equity stood at KRW 31.8 billion at end-2025, but quarterly losses and share issuance in 2026 mean the multiples can shift from quarter to quarter. The dividend yield is effectively nil, so dividend-based comparison is difficult.

Operating margin improved from -4,833.0% in 2022 to -313.9% in 2025 but remains in loss territory, so profitability-based valuation depends on a shift from losses to profit. Without an earnings base, the price-to-book ratio, sales growth and the operating loss trend become the main reference points.

The debt ratio fell to 46.4%, improving the capital structure, but equity figures could be reinterpreted depending on the outcome of the re-audit.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Rapid sales expansion

Sales for 2025 were KRW 3.43 billion, up 2,736.7% year on year, and third-quarter 2026 sales of KRW 689 million rose 51.3% year on year. Sales have grown for two consecutive quarters since the second quarter of 2026. The company says KRW 3.1 billion of 2025 sales came from its AI drug discovery platform business. The company presents platform-based contracts as evidence that the business model is commercially viable.

Pipeline and joint research results

In November 2026 the company said joint research with MSK produced hit compounds for two drug targets. In September 2026 it announced bio-better candidates across eight targets from its Ab-ARS platform. It has disclosed seven proprietary candidates and aims for clinical entry. Specific target details have not been released ahead of follow-up papers and IP protection.

Balance sheet and narrower losses

The debt ratio fell to 46.4% at end-2025 from 75.3% in 2024, and total equity was KRW 31.8 billion. Press reports say debt was converted into equity through a convertible bond conversion and a rights offering. Operating loss narrowed to KRW 10.8 billion in 2025 from KRW 14.3 billion in 2024. The company set breakeven in 2026 as a business goal.

09

Bear factors

Continuing losses and operating cash outflows

Losses have run for four consecutive years from 2022 to 2025, and operating cash flow was negative in each year. Operating loss widened to KRW 3.67 billion in the third quarter of 2026 from KRW 2.22 billion in the second.

Net loss attributable to controlling shareholders for the four quarters from the fourth quarter of 2025 through the third quarter of 2026 totaled KRW 14 billion. The timing of a shift to profit can be gauged by whether the 2026 breakeven goal is reached.

Contract cancellations and quarterly volatility

Two agreements with Kymera Therapeutics, totaling about KRW 534 million, were terminated after all three projects were stopped, so about KRW 610 million in milestone payments will not be received. Compound purchase and delivery costs of about KRW 120 million were settled but not booked as revenue.

After fourth-quarter 2025 sales of KRW 1.76 billion, first-quarter 2026 sales of KRW 422 million fell 76.0% from the prior quarter. Large swings in quarterly sales are cited as a bearish factor for earnings continuity.

Audit opinion and internal control issues

The company received a review opinion refusal on its 2026 half-year financial statements from Samjung Accounting Corp., which it attributes to a scope limitation on evidence. The auditor also flagged the legitimacy of lending transactions and compliance with internal controls.

The company is pursuing a re-audit and management normalization. Share-backed loans from the largest shareholder and related-party lending are cited as uncertainties in internal management.

10

Risk factors

Financial reporting and audit

Restoring confidence in the financial statements is a priority after the review opinion refusal on the 2026 half-year statements and the decision to pursue a re-audit. The company says it aims to exit the investment-caution designation after re-audit and management normalization. The 2025 audit report received a clean opinion, but the later half-year review drew a refusal.

Funding and dilution

The payment date for a KRW 2 billion third-party share placement was moved to November 17, 2026, and a public offering of KRW 3 billion or more is under review. Convertible bond put option exercises rose in 2025 and added liquidity pressure. A larger share issuance could dilute the stakes of existing shareholders.

Concentration and contract volatility

Revenue relies on joint research and individual contracts, so a partner halting a project can quickly reduce sales. The Kymera case shows how a counterparty's project stoppage can wipe out performance fees. The proprietary pipeline is at the preclinical stage and needs time and funding to reach clinic. Press reports say the company has not finalized a plan to run clinical trials itself.

11

What to watch next

  1. November 30, 2026

    The date the two Kymera agreements take effect. The master agreement remains in place, so the effect of the cancellation on later quarterly sales is the point to check.

  2. December 31, 2026

    Whether the company secures the 18 or more pre-IND development candidates it targeted by year-end, including 10 or more bio-better, 3 or more small-molecule improved drugs and 5 or more drug repurposing candidates.

  3. After year-end 2026 (schedule not set)

    Whether the re-audit clears the review opinion refusal on the 2026 half-year statements and whether the company meets the conditions to exit the investment-caution designation.

  4. By March 31, 2027 (annual report filing deadline)

    The 2026 annual report will disclose full-year 2026 sales and operating loss, showing whether the breakeven target was reached. Fourth-quarter 2026 results will be included in this report.

12

Overall view

SyntekaBio's 2025 sales of KRW 3.43 billion, up 2,736.7%, show in numbers the shift of its AI drug discovery platform toward revenue.

Operating loss narrowed to KRW 10.8 billion in the same year, but net loss attributable to controlling shareholders widened to KRW 17.4 billion, and losses have continued for four consecutive years from 2022.

Quarterly sales in 2026 stayed in the hundreds of millions of won, and operating loss widened to KRW 3.67 billion in the third quarter. On the other hand, the MSK hit compounds, bio-better candidates across eight targets and seven disclosed pipeline candidates mark progress in technology validation.

The debt ratio fell to 46.4% and the capital structure improved, but the 2026 half-year review opinion refusal, the re-audit, the possible expansion of share issuance and the Kymera cancellation remain burdens on financial credibility and funding.

Bullish and bearish factors coexist, and the next checkpoint is the 2026 annual report's full-year operating loss and whether the breakeven goal is met. This report is for information only and does not include a buy or sell opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. core.asiae.co.kr
  2. sisajournal-e.com
  3. supple.kr
  4. press9.kr
  5. news.nate.com
  6. pharmnews.com
  7. press9.kr
  8. pharm.edaily.co.kr
  9. m.comp.fnguide.com
  10. pharm.edaily.co.kr
  11. view.asiae.co.kr
  12. m.news.nate.com
  13. kndaily.co.kr
  14. view.asiae.co.kr
  15. news.nate.com
  16. pharmnews.com
  17. mt.co.kr
  18. mt.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis